BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 23378341)

  • 1. FOXO3a is a major target of inactivation by PI3K/AKT signaling in aggressive neuroblastoma.
    Santo EE; Stroeken P; Sluis PV; Koster J; Versteeg R; Westerhout EM
    Cancer Res; 2013 Apr; 73(7):2189-98. PubMed ID: 23378341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphorylation of FOXO3a by PI3K/Akt pathway in HK-2 renal proximal tubular epithelial cells exposed to cadmium.
    Fujiki K; Inamura H; Matsuoka M
    Arch Toxicol; 2013 Dec; 87(12):2119-27. PubMed ID: 23673518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting aberrant PI3K/Akt activation by PI103 restores sensitivity to TRAIL-induced apoptosis in neuroblastoma.
    Opel D; Naumann I; Schneider M; Bertele D; Debatin KM; Fulda S
    Clin Cancer Res; 2011 May; 17(10):3233-47. PubMed ID: 21355080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activated phosphatidylinositol 3-kinase/Akt inhibits the transition of endothelial progenitor cells to mesenchymal cells by regulating the forkhead box subgroup O-3a signaling.
    Zhang Z; Zhang T; Zhou Y; Wei X; Zhu J; Zhang J; Wang C
    Cell Physiol Biochem; 2015; 35(4):1643-53. PubMed ID: 25824462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The inhibition of activated hepatic stellate cells proliferation by arctigenin through G0/G1 phase cell cycle arrest: persistent p27(Kip1) induction by interfering with PI3K/Akt/FOXO3a signaling pathway.
    Li A; Wang J; Wu M; Zhang X; Zhang H
    Eur J Pharmacol; 2015 Jan; 747():71-87. PubMed ID: 25498792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma growth in vitro and in vivo.
    Segerström L; Baryawno N; Sveinbjörnsson B; Wickström M; Elfman L; Kogner P; Johnsen JI
    Int J Cancer; 2011 Dec; 129(12):2958-65. PubMed ID: 21717457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Forkhead Box Transcription Factor (FOXO3a) mediates the cytotoxic effect of vernodalin in vitro and inhibits the breast tumor growth in vivo.
    Ananda Sadagopan SK; Mohebali N; Looi CY; Hasanpourghadi M; Pandurangan AK; Arya A; Karimian H; Mustafa MR
    J Exp Clin Cancer Res; 2015 Dec; 34():147. PubMed ID: 26643256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
    Guenther MK; Graab U; Fulda S
    Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quinazoline based small molecule exerts potent tumour suppressive properties by inhibiting PI3K/Akt/FoxO3a signalling in experimental colon cancer.
    Qazi AK; Hussain A; Khan S; Aga MA; Behl A; Ali S; Singh SK; Taneja SC; Shah BA; Saxena AK; Mondhe DM; Hamid A
    Cancer Lett; 2015 Apr; 359(1):47-56. PubMed ID: 25554016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sohlh2 inhibits the apoptosis of mouse primordial follicle oocytes via C-kit/PI3K/Akt/Foxo3a signalling pathway.
    Zhang X; Zhang H; Gao Q; Ji S; Bing L; Hao J
    Reprod Biomed Online; 2015 May; 30(5):514-21. PubMed ID: 25773528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The PI3K/Akt/FOXO3a/p27Kip1 signaling contributes to anti-inflammatory drug-suppressed proliferation of human osteoblasts.
    Li CJ; Chang JK; Chou CH; Wang GJ; Ho ML
    Biochem Pharmacol; 2010 Mar; 79(6):926-37. PubMed ID: 19883628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of PI3K/Akt/FoxO3a and PKA/CREB Signaling Pathways in the Protective Effect of Fluoxetine Against Corticosterone-Induced Cytotoxicity in PC12 Cells.
    Zeng B; Li Y; Niu B; Wang X; Cheng Y; Zhou Z; You T; Liu Y; Wang H; Xu J
    J Mol Neurosci; 2016 Aug; 59(4):567-78. PubMed ID: 27412469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Akt-FOXO3a signaling axis dysregulation in human oral squamous cell carcinoma and potent efficacy of FOXO3a-targeted gene therapy.
    Fang L; Wang H; Zhou L; Yu D
    Oral Oncol; 2011 Jan; 47(1):16-21. PubMed ID: 21109483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydrogen sulfide protects H9c2 cardiac cells against doxorubicin-induced cytotoxicity through the PI3K/Akt/FoxO3a pathway.
    Liu MH; Zhang Y; He J; Tan TP; Wu SJ; Guo DM; He H; Peng J; Tang ZH; Jiang ZS
    Int J Mol Med; 2016 Jun; 37(6):1661-8. PubMed ID: 27081862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway.
    Guo S; Sonenshein GE
    Mol Cell Biol; 2004 Oct; 24(19):8681-90. PubMed ID: 15367686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Helicobacter pylori-associated regulation of forkhead transcription factors FoxO1/3a in human gastric cells.
    Tabassam FH; Graham DY; Yamaoka Y
    Helicobacter; 2012 Jun; 17(3):193-202. PubMed ID: 22515357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FoxO3a functions as a key integrator of cellular signals that control glioblastoma stem-like cell differentiation and tumorigenicity.
    Sunayama J; Sato A; Matsuda K; Tachibana K; Watanabe E; Seino S; Suzuki K; Narita Y; Shibui S; Sakurada K; Kayama T; Tomiyama A; Kitanaka C
    Stem Cells; 2011 Sep; 29(9):1327-37. PubMed ID: 21793107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOXO3a reactivation mediates the synergistic cytotoxic effects of rapamycin and cisplatin in oral squamous cell carcinoma cells.
    Fang L; Wang H; Zhou L; Yu D
    Toxicol Appl Pharmacol; 2011 Feb; 251(1):8-15. PubMed ID: 21092744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOXO3a mediates the cytotoxic effects of cisplatin in lung cancer cells.
    Liu H; Yin J; Wang C; Gu Y; Deng M; He Z
    Anticancer Drugs; 2014 Sep; 25(8):898-907. PubMed ID: 24814195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOXO3a: a novel player in thyroid carcinogenesis?
    Karger S; Weidinger C; Krause K; Sheu SY; Aigner T; Gimm O; Schmid KW; Dralle H; Fuhrer D
    Endocr Relat Cancer; 2009 Mar; 16(1):189-99. PubMed ID: 18845647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.